ClinicalTrials.gg
CompletedNCT00889720Updated Oct 17, 2011Results posted

A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery

A Phase 4 interventional study of Varenicline in Smoking Cessation, sponsored by Pfizer. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-17.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
103rd of 110
16 · median 209
Started
2009
with 10 others
Phase 4
47 of 110
3 open now
Registered
38th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 103rd largest by enrollment, is one of 11 that started in 2009, is one of 47 in phase 4, and was the 38th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

It is possible to offer smoking cessation treatment including varenicline to patients scheduled for elective surgery. This study will evaluate whether or not this will enable some patients to quit smoking for up to 4 weeks prior to surgery and in turn, whether this may lead to reductions in post-operative complication such as wound infections.

Read the detailed description

Recruitment to this study was terminated (on February 23, 2010) earlier than originally planned because recruitment was much slower than expected and therefore the study has already achieved its main objective of assessing the feasibility of conducting a larger study of similar design to investigate the efficacy of smoking cessation therapy in a pre-surgical setting. The decision to end recruitment to the trial was not based on any safety concerns.

03

Conditions studied

  • Smoking Cessation

Keywords

  • smoking cessation
  • varenicline
  • elective surgery
  • wound infections
  • post-operative complications
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Smokers motivated to stop smoking scheduled for elective surgery

Exclusion criteria

Exclusion Criteria:

  • Current or recent depression
  • Current or recent suicidal ideation
  • Uncontrolled or unstable medical condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Smoking cessation tratment including varenicline

    Drug: Varenicline

Interventions

  • Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd

    Also known as: Champix

06

What researchers measure

Primary outcomes

  1. Percentage of Fully Compliant Participants

    Compliance defined as completed 12 weeks of varenicline therapy, underwent surgery 8 weeks +-10 days after start of varenicline treatment, and had evaluations of wound infection 1 to 3 days and 6 to 10 days after surgery.

    Time frame: Baseline through Week 12

  2. Number of Participants With Surgical Site Infection Post-surgery Days 1 to 3: Center for Disease Control (CDC) Definition

    Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

    Time frame: Post-surgery Days 1-3

  3. Number of Participants With Surgical Site Infection Post-surgery Days 6 to 10: Center for Disease Control (CDC) Definition

    Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

    Time frame: Post-surgery Days 6-10

  4. Number of Participants With Surgical Site Infection at Week 12: Center for Disease Control (CDC) Definition

    Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

    Time frame: Week 12

  5. Number of Participants With Surgical Site Infection at Week 26: Center for Disease Control (CDC) Definition

    Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

    Time frame: Week 26

  6. Number of Participants With Surgical Site Infections With Microbiological Confirmation of Bacterial Infection

    Microbiological confirmation defined as organisms isolated from an aseptically obtained culture of fluid or tissues from the superficial incision.

    Time frame: Post-surgery Days 1-3, Post-surgery Days 6-10, Week 12, Week 26

  7. Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections Post-surgery Days 1 to 3: Southampton Wound Assessment Scale

    Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

    Time frame: Post-surgery Days 1-3

  8. Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections Post-surgery Days 6 to 10: Southampton Wound Assessment Scale

    Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

    Time frame: Post-surgery Days 6-10

  9. Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections at Week 12: Southampton Wound Assessment Scale

    Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

    Time frame: Week 12

  10. Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections at Week 26: Southampton Wound Assessment Scale

    Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

    Time frame: Week 26

  11. Wound Healing Grade by ASEPSIS Criteria: Post-surgery Days 1 to 3

    Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

    Time frame: Post-surgery Days 1-3

  12. Wound Healing Grade by ASEPSIS Criteria: Post-surgery Days 6 to 10

    Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

    Time frame: Post-surgery Days 6-10

  13. Wound Healing Grade by ASEPSIS Criteria at Week 12

    Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

    Time frame: Week 12

  14. Wound Healing Grade by ASEPSIS Criteria at Week 26

    Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

    Time frame: Week 26

  15. Number of Participants With 7 Day Point Prevalence (PP) for Smoking Abstinence Prior to Hospital Admission.

    Responder defined as participant who answered "No" to question on Nicotine Use Inventory (NUI), "Has the subject smoked any cigarettes or cigarillos or used any other nicotine containing products in the last 7 days?" Additionally, responder status confirmed by measurement of end-expiratory exhaled carbon monoxide concentration \<10 parts per million (ppm).

    Time frame: 7 days prior to hospital admission to day of hospital admission (after Week 8 of treatment)

Secondary outcomes

  1. Number of Participants by Severity of Post-operative Complications: Dindo, Demartines and Clavien Classification System

    Grade 0: no post-operative (post-op) complications (comp), Grade 1: any deviation from normal post-op course without need for pharmacological treatment (PT) other than allowed interventions (INT), or surgical, endoscopic or radiological INT; Grade II: required PT with drugs other than those allowed for grade I comp; Grade III required surgical, endoscopic or radiological INT, IIIa: not under general anaesthesia (GA), IIIb: under GA; Grade IV: life-threatening comp requiring IC/ICU management, IVa: single organ dysfunction (DSF), IVb: multiorgan DSF; Grade V: death. Not done = not assessed.

    Time frame: Baseline through Week 26

  2. Percentage of Participants Who Succeed in Reducing Their Cigarette Consumption by at Least 50% in 7 Days Preceding Hospital Admission Compared With Baseline.

    Time frame: Baseline, Week 8

  3. Number of Participants With 7-day Point Prevalence (PP) for Abstinence From Cigarette Smoking and Other Nicotine Use at the End of Treatment (Week 12)

    Responder defined as participant who answered "No" to question on Nicotine Use Inventory (NUI), "Has the subject smoked any cigarettes or cigarillos or used any other nicotine containing products in the last 7 days?" Additionally, responder status confirmed by measurement of end-expiratory exhaled carbon monoxide concentration \<10 parts per million (ppm).

    Time frame: Week 12

  4. Number of Participants With 7 Day Point Prevalence (PP) for Abstinence in the Week Preceding Week 26

    Responder defined as participant who answered "No" to question on Nicotine Use Inventory (NUI), "Has the subject smoked any cigarettes or cigarillos or used any other nicotine containing products in the last 7 days?" Additionally, responder status confirmed by measurement of end-expiratory exhaled carbon monoxide concentration \<10 parts per million (ppm).

    Time frame: Week 26

  5. Percentage of Participants Who Reduced Their Cigarette Consumption by at Least 50% in the 7 Days Preceding Weeks 12 and 26 Compared With Baseline.

    Time frame: Baseline, Week 12, Week 26

  6. Number of Participants With Treatment-Emergent Adverse Events by Type, Severity, Seriousness, and Relatedness to Varenicline

    Treatment-emergent AE (TEAE): any untoward medical occurrence that occurred or worsened after beginning study treatment without regard to causal relationship. Treatment-related TEAE: investigator assessment of reasonable possibility that treatment caused or contributed to AE. Severe TEAE: interfered significantly with usual function. SAE: AE resulting in death, initial or prolonged inpatient hospitalization, a life-threatening experience (immediate risk of death), persistent or significant disability/incapacity, congenital anomaly, or deemed significant for any other reason.

    Time frame: Baseline through Week 26 (within 30 days of last dose)

  7. Number of Treatment Emergent Adverse Events by Severity

    Mild: did not interfere with usual function; Moderate: interfered to some extent with usual function; Severe: interfered significantly with usual function. If the same participant in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence was taken. Missing baseline severities were imputed as mild.

    Time frame: Baseline through Week 26 (within 30 days of last dose)

07

Results

Posted Aug 25, 2011
Limitations and caveats
This study was terminated after 16 of 100 planned subjects were enrolled due to slow recruitment and non-compliance with the protocol; only selected efficacy listings of the surgical population and key safety data were reported.

Participant flow

Participant flow — Overall Study
MilestoneVarenicline
Started16
Surgical population12
Completed8
Not completed8
Withdrew: Withdrawal by subject4
Withdrew: Other4

Outcome measures

PrimaryPercentage of Fully Compliant Participants

Compliance defined as completed 12 weeks of varenicline therapy, underwent surgery 8 weeks +-10 days after start of varenicline treatment, and had evaluations of wound infection 1 to 3 days and 6 to 10 days after surgery.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Fully Compliant Participants
percentage of participantsVarenicline
Percentage of Fully Compliant Participants0
PrimaryNumber of Participants With Surgical Site Infection Post-surgery Days 1 to 3: Center for Disease Control (CDC) Definition

Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

Time frame:
Post-surgery Days 1-3
Reported as:
Number · participants
Number of Participants With Surgical Site Infection Post-surgery Days 1 to 3: Center for Disease Control (CDC) Definition
participantsVarenicline
Category 0: no surgical wound complications11
Not done1
PrimaryNumber of Participants With Surgical Site Infection Post-surgery Days 6 to 10: Center for Disease Control (CDC) Definition

Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

Time frame:
Post-surgery Days 6-10
Reported as:
Number · participants
Number of Participants With Surgical Site Infection Post-surgery Days 6 to 10: Center for Disease Control (CDC) Definition
participantsVarenicline
Category 0: no surgical wound complications11
Not Done1
PrimaryNumber of Participants With Surgical Site Infection at Week 12: Center for Disease Control (CDC) Definition

Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Surgical Site Infection at Week 12: Center for Disease Control (CDC) Definition
participantsVarenicline
Category 0: no surgical wound complications9
Not done2
PrimaryNumber of Participants With Surgical Site Infection at Week 26: Center for Disease Control (CDC) Definition

Surgical site infections (SSIs) assessed by 1992 CDC definition; divided into incisional and organ/space SSIs. Incisional space SSIs further classified as involving only skin and subcutaneous tissue (superficial incisional) or involving deep soft tissues (fascial and muscle layers) of the incision (deep incisional ). Organ/space SSIs involve any part of the anatomy (organs or spaces) other than incision opened or manipulated during operative procedure. None = did not have a surgical site infection. Category 0 = no surgical wound complications. Not done = not assessed.

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants With Surgical Site Infection at Week 26: Center for Disease Control (CDC) Definition
participantsVarenicline
Category 0: no surgical wound complications9
Not done0
PrimaryNumber of Participants With Surgical Site Infections With Microbiological Confirmation of Bacterial Infection

Microbiological confirmation defined as organisms isolated from an aseptically obtained culture of fluid or tissues from the superficial incision.

Time frame:
Post-surgery Days 1-3, Post-surgery Days 6-10, Week 12, Week 26
Reported as:
Number · participants

No measurements were reported for this outcome.

PrimaryNumber of Participants With Grade of Wound Healing and Severity of Surgical Site Infections Post-surgery Days 1 to 3: Southampton Wound Assessment Scale

Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

Time frame:
Post-surgery Days 1-3
Reported as:
Number · participants
Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections Post-surgery Days 1 to 3: Southampton Wound Assessment Scale
participantsVarenicline
Grade 010
Grade Ia1
Not done1
PrimaryNumber of Participants With Grade of Wound Healing and Severity of Surgical Site Infections Post-surgery Days 6 to 10: Southampton Wound Assessment Scale

Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

Time frame:
Post-surgery Days 6-10
Reported as:
Number · participants
Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections Post-surgery Days 6 to 10: Southampton Wound Assessment Scale
participantsVarenicline
Grade 08
Grade Ia1
Grade IIa1
Grade IIb1
Not done1
PrimaryNumber of Participants With Grade of Wound Healing and Severity of Surgical Site Infections at Week 12: Southampton Wound Assessment Scale

Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections at Week 12: Southampton Wound Assessment Scale
participantsVarenicline
Grade 08
Grade Ia1
Not done2
PrimaryNumber of Participants With Grade of Wound Healing and Severity of Surgical Site Infections at Week 26: Southampton Wound Assessment Scale

Grade 0 = normal healing (NH); Grade I = NH with (w) mild bruising (br) or haematoma (a: some br, b: considerable br, c: mild erythema); Grade II= erythema plus other signs of inflammation (a: at 1 point, b: around sutures, c: along wnd, d: around wnd); Grade III= clear or haemoserous discharge (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm, c: large volume, D: prolonged \> 3 days); Grade IV= pus (a: at 1 point only ≤ 2 cm, b: along wnd \> 2 cm; Grade V=deep or severe wnd infection (w or without tissue breakdown; haematoma requiring aspiration). Not done = not assessed.

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections at Week 26: Southampton Wound Assessment Scale
participantsVarenicline
Grade 08
Not done1
PrimaryWound Healing Grade by ASEPSIS Criteria: Post-surgery Days 1 to 3

Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

Time frame:
Post-surgery Days 1-3
Reported as:
Number · participants
Wound Healing Grade by ASEPSIS Criteria: Post-surgery Days 1 to 3
participantsVarenicline
Satisfactory healing7
Not done1
PrimaryWound Healing Grade by ASEPSIS Criteria: Post-surgery Days 6 to 10

Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

Time frame:
Post-surgery Days 6-10
Reported as:
Number · participants
Wound Healing Grade by ASEPSIS Criteria: Post-surgery Days 6 to 10
participantsVarenicline
Satisfactory healing7
Not done1
PrimaryWound Healing Grade by ASEPSIS Criteria at Week 12

Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

Time frame:
Week 12
Reported as:
Number · participants
Wound Healing Grade by ASEPSIS Criteria at Week 12
participantsVarenicline
Satisfactory healing6
Not done1
PrimaryWound Healing Grade by ASEPSIS Criteria at Week 26

Wound grading scale of wound characteristics assessed by portion of wound infected and point scale for daily wound inspection. Infections categorized by ASEPSIS score as satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (21-30), moderate wound infection (31-40), and severe wound infection (\>40). Surgical site complication defined as total score \>10; wound infection defined as total score \>20. Not done = not assessed.

Time frame:
Week 26
Reported as:
Number · participants
Wound Healing Grade by ASEPSIS Criteria at Week 26
participantsVarenicline
Satisfactory healing6
Not done0
PrimaryNumber of Participants With 7 Day Point Prevalence (PP) for Smoking Abstinence Prior to Hospital Admission.

Responder defined as participant who answered "No" to question on Nicotine Use Inventory (NUI), "Has the subject smoked any cigarettes or cigarillos or used any other nicotine containing products in the last 7 days?" Additionally, responder status confirmed by measurement of end-expiratory exhaled carbon monoxide concentration \<10 parts per million (ppm).

Time frame:
7 days prior to hospital admission to day of hospital admission (after Week 8 of treatment)
Reported as:
Number · participants
Number of Participants With 7 Day Point Prevalence (PP) for Smoking Abstinence Prior to Hospital Admission.
participantsVarenicline
Number of Participants With 7 Day Point Prevalence (PP) for Smoking Abstinence Prior to Hospital Admission.9
SecondaryNumber of Participants by Severity of Post-operative Complications: Dindo, Demartines and Clavien Classification System

Grade 0: no post-operative (post-op) complications (comp), Grade 1: any deviation from normal post-op course without need for pharmacological treatment (PT) other than allowed interventions (INT), or surgical, endoscopic or radiological INT; Grade II: required PT with drugs other than those allowed for grade I comp; Grade III required surgical, endoscopic or radiological INT, IIIa: not under general anaesthesia (GA), IIIb: under GA; Grade IV: life-threatening comp requiring IC/ICU management, IVa: single organ dysfunction (DSF), IVb: multiorgan DSF; Grade V: death. Not done = not assessed.

Time frame:
Baseline through Week 26
Reported as:
Number · participants
Number of Participants by Severity of Post-operative Complications: Dindo, Demartines and Clavien Classification System
participantsVarenicline
1-3 days PS: No post-operative complications10
1-3 days PS: Grade II1
1-3 days PS: Not done1
6-10 days PS: No post-operative complications7
6-10 days PS: Grade I3
6-10 days PS: Grade II1
6-10 days PS: Not done1
Week 12: No post-operative complications7
Week 12: Grade II1
Week 12: Grade IIIb1
Week 12: Not done2
Week 26: No post-operative complications8
Week 26: Grade IIIb1
SecondaryPercentage of Participants Who Succeed in Reducing Their Cigarette Consumption by at Least 50% in 7 Days Preceding Hospital Admission Compared With Baseline.
Time frame:
Baseline, Week 8
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With 7-day Point Prevalence (PP) for Abstinence From Cigarette Smoking and Other Nicotine Use at the End of Treatment (Week 12)

Responder defined as participant who answered "No" to question on Nicotine Use Inventory (NUI), "Has the subject smoked any cigarettes or cigarillos or used any other nicotine containing products in the last 7 days?" Additionally, responder status confirmed by measurement of end-expiratory exhaled carbon monoxide concentration \<10 parts per million (ppm).

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With 7-day Point Prevalence (PP) for Abstinence From Cigarette Smoking and Other Nicotine Use at the End of Treatment (Week 12)
participantsVarenicline
Number of Participants With 7-day Point Prevalence (PP) for Abstinence From Cigarette Smoking and Other Nicotine Use at the End of Treatment (Week 12)9
SecondaryNumber of Participants With 7 Day Point Prevalence (PP) for Abstinence in the Week Preceding Week 26

Responder defined as participant who answered "No" to question on Nicotine Use Inventory (NUI), "Has the subject smoked any cigarettes or cigarillos or used any other nicotine containing products in the last 7 days?" Additionally, responder status confirmed by measurement of end-expiratory exhaled carbon monoxide concentration \<10 parts per million (ppm).

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants With 7 Day Point Prevalence (PP) for Abstinence in the Week Preceding Week 26
participantsVarenicline
Number of Participants With 7 Day Point Prevalence (PP) for Abstinence in the Week Preceding Week 267
SecondaryPercentage of Participants Who Reduced Their Cigarette Consumption by at Least 50% in the 7 Days Preceding Weeks 12 and 26 Compared With Baseline.
Time frame:
Baseline, Week 12, Week 26
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events by Type, Severity, Seriousness, and Relatedness to Varenicline

Treatment-emergent AE (TEAE): any untoward medical occurrence that occurred or worsened after beginning study treatment without regard to causal relationship. Treatment-related TEAE: investigator assessment of reasonable possibility that treatment caused or contributed to AE. Severe TEAE: interfered significantly with usual function. SAE: AE resulting in death, initial or prolonged inpatient hospitalization, a life-threatening experience (immediate risk of death), persistent or significant disability/incapacity, congenital anomaly, or deemed significant for any other reason.

Time frame:
Baseline through Week 26 (within 30 days of last dose)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events by Type, Severity, Seriousness, and Relatedness to Varenicline
participantsVarenicline
TEAE: all causalities9
TEAE: treatment-related8
Severe TEAE: all causalities3
Severe TEAE: treatment-related1
SAE: all causalities1
SAE: treatment-related0
SecondaryNumber of Treatment Emergent Adverse Events by Severity

Mild: did not interfere with usual function; Moderate: interfered to some extent with usual function; Severe: interfered significantly with usual function. If the same participant in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence was taken. Missing baseline severities were imputed as mild.

Time frame:
Baseline through Week 26 (within 30 days of last dose)
Reported as:
Number · events
Number of Treatment Emergent Adverse Events by Severity
eventsVarenicline
Mild13
Moderate11
Severe4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—1/16 (6.3%)9/16 (56.3%)
Most frequent serious events
Most frequent serious events
EventVarenicline
Intestinal obstructionGastrointestinal disorders1/16
Most frequent other events
Showing 10 of 21
Most frequent other events
EventVarenicline
NauseaGastrointestinal disorders3/16
InsomniaPsychiatric disorders3/16
VomitingGastrointestinal disorders2/16
Decreased appetiteMetabolism and nutrition disorders2/16
TachycardiaCardiac disorders1/16
Abdominal painGastrointestinal disorders1/16
DyspepsiaGastrointestinal disorders1/16
AstheniaGeneral disorders1/16
Feeling abnormalGeneral disorders1/16
GastroenteritisInfections and infestations1/16

Baseline characteristics

Age, Customized
Age, Customized(Participants)Varenicline
Between 18 and 44 years6
Between 45 and 64 years7
>= 65 years3
Sex: Female, Male
Sex: Female, Male(Participants)Varenicline
Female7
Male9
08

Study locations

2 sites
  • Pfizer Investigational Site
    Paris Cedex 13, 75651, France
  • Pfizer Investigational Site
    Pisa, 56124, Italy
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2009
First posted
Apr 29, 2009
Start
Nov 2009
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Aug 25, 2011
Last update
Oct 17, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00889720
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 29, 2009
Start date
Nov 2009
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Aug 25, 2011
Last update
Oct 17, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion